Nolato Medical expands its operations in China

        Print
| Source: Nolato AB
Nolato is expanding its Chinese production facility with an additional 2,200
square metres, of which around 800 square metres will be clean room of the
highest standard in accordance with ISO 14644-1:1999, class 8.

“China is the fastest growing market for pharmaceuticals and medical devices,
which means that more and more of our customers are discussing expanded
production in China for the Asian market,” says Christer Wahlquist, President of
the Nolato Medical business area. The expansion, which will accommodate around
30 injection moulding machines, is being made to allow us to stay one step ahead
of our customers and secure resources for future growth in China.

“Our philosophy is to be a close, long-term and reliable partner who can offer
our customers global development and production facilities. The new facility
will satisfy even the most demanding requirements of our customers,” Christer
Wahlquist adds.

Nolato Medical has been active in China since 2008. Overall, Nolato Medical has
around 25,000 square metres of clean room capacity in a range of classes at nine
facilities in Asia, Europe and North America.

-----

For further information, please contact:
Hans Porat, President and CEO, +46 (0)705 517550
Christer Wahlquist, President of Nolato Medical, +46 (0)705 804848

The Nolato Group is a high-tech developer and manufacturer of polymer product
systems for leading customers in medical devices, telecommunications, hygiene,
automotive products and other selected industrial sectors. Nolato’s shares are
quoted on the NASDAQ OMX Nordic Exchange, Stockholm Mid Cap segment, where they
are included in the Industrial sector. www.nolato.se

The Nolato Medical business area has sales of approximately SEK 1.2 billion and
nearly 1,000 employees at units in Sweden, Great Britain, Hungary, USA and
China.

The information contained in this press release is the information which Nolato
must make public in accordance with the Swedish Securities Market Act and/or the
Swedish Financial Instruments Trading Act. The information was submitted for
publication July 2, 2013, at 8.25am.